FutureWorld (FWDG) Receives Major Shipment of CBD Oil for CBD-based Pharmaceuticals & Nutraceutical

Company to Process CBD Oil for Nutraceutical and Infusion through CB Scientific and URVape


ST. PETERSBURG, Fla., Dec. 10, 2014 (GLOBE NEWSWIRE) -- FutureWorld Corp. (OTCQB; FWDG), a leading provider of advanced technologies and solutions to the global cannabis industry, announces today that the Company has received its first major shipment of organic, high quality, CBD oil, for the purpose of distributing CBD-based Pharmaceuticals & Nutraceutical products. The Company has spent months in resources to locate quality organic CBD oil, toxin and heavy metal free, for the US market. We are pleased that we have reached this important milestone for the Company and its future. 

The Company will process the CBD oil for multiple Nutraceutical and Infusion companies through URVape and CB Scientific. URVape has designed specialty cartridges or atomizers for the vaporizing of CBD. Both CB Scientific and URVape will be selling and distributing high quality organic CBD oil by mid December 2014.  The Company is expecting to deliver to the market as much as several thousand kilograms of organic high-quality CBD oil by the end of 2015 through exclusive agreements with Hemp farmers globally.  The company projects a significant increase in revenues from sales of these products.

We suggest companies and individuals in need of high quality organic CBD Hemp oil for infused, vaporizing or medical purposes, to contact FutureWorld at; cbdoil@futureworldcorp.com. 

The industrial hemp oil-based Cannabidiol (CBD) nutritional supplement, wellness and personal care products will become one of the biggest markets nationally. The global Nutraceutical market is projected to be in excess of $200 billion by 2015 and the current US Nutraceutical and Dietary supplement market is valued at around $42 billion. The infusion of the Cannabidiol (CBD) based products into this massive marketplace will create significant opportunities for the first movers. FutureWorld through CB Scientific and URVape will be part of this significant opportunity. 

Cannabinoids (non-psychoactive CBD) have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and auto-immune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and HIV dementia.

About FutureWorld Corp

FutureWorld (Other OTCQB: FWDG), a Delaware corporation, is a U.S. Diversified Holding Company formed to capitalize on the burgeoning Cannabis markets globally. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products, such as industrial Hemp. FutureWorld, through its subsidiaries such as HempTech and CB Scientific, provides personal and professional THC and CBD test kits, pure CBD oil solutions, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. Our wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana. 

To request further information about FutureWorld, please email us at investors@futureworldcorp.com, log onto our website at http://www.futureworldcorp.com or visit us at our Facebook page https://www.facebook.com/futureworldenergy or on Twitter #futureworldinc. 

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.



            

Contact Data